Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
45 studies found for:    " June 03, 2008":" July 03, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Sleep Quality and Presence of Sleep Disordered Breathing
Conditions: HIV Infections;   Sleep
22 Completed Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
Conditions: Opioid-related Disorders;   HIV Infections;   Hepatitis C, Chronic;   Depression
Interventions: Behavioral: MET/CBT based individualized counseling;   Drug: Buprenorphine
23 Completed Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
Condition: HIV Infections
Intervention: Drug: VRC-HIVADV014-00-VP
24 Completed VENICE Study Nevirapine Full Dose/Dose Escalation
Condition: HIV Infections
Intervention: Drug: nevirapine
25 Completed Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks
Condition: HIV Infections
Interventions: Behavioral: Network leader training;   Behavioral: Standard HIV risk-reduction counseling
26 Active, not recruiting Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations
Condition: HIV Infections
Interventions: Behavioral: Face-to-face training;   Behavioral: Distance training;   Behavioral: Popular Opinion Leader (POL)
27 Completed
Has Results
Kaletra-isentress Treatment Evaluation
Condition: HIV Infections
Interventions: Drug: Kaletra + Isentress;   Drug: Pre-study antiretroviral regimen
28 Completed Impact of an HPV Vaccine in HIV-Infected Young Women
Condition: HIV Infection
Intervention: Biological: HPV vaccine for strains -6, -11, -16, and -18
29 Unknown  Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection
Conditions: Latent Tuberculosis Infection;   HIV Infections;   Tuberculosis
30 Completed Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.
Condition: Tuberculosis (TB)
Interventions: Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342;   Biological: Control vaccine with the adjuvant system.;   Biological: Control vaccine with physiological saline
31 Completed
Has Results
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Placebo
32 Withdrawn Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort
Condition: HIV Infections
Intervention: Drug: Tipranavir
33 Completed
Has Results
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
Condition: HIV Infections
Intervention: Drug: Maraviroc
34 Withdrawn Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Conditions: HIV Infections;   Heroin Dependence
Interventions: Behavioral: Directly Administered Antiretroviral Therapy (DAART);   Behavioral: SAT
35 Completed
Has Results
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
Condition: HIV Infections
Interventions: Biological: (PV) 23-valent pneumococcal polysaccharide vaccine;   Biological: Placebo
36 Completed Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
Condition: HIV Infections
Interventions: Drug: Vicriviroc maleate;   Drug: Placebo;   Drug: Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg
37 Completed Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
Condition: HIV Infections
Intervention: Drug: Maraviroc
38 Completed Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects
Conditions: HIV Infections;   Adverse Effects
Intervention: Behavioral: Cognitive-behavioral therapy
39 Completed
Has Results
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Condition: Human Immunodeficiency Virus Infection
Interventions: Drug: lopinavir/ritonavir (LPV/r);   Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF);   Drug: raltegravir (RAL)
40 Completed Linkage to Care - Part I
Condition: HIV

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Indicates status has not been verified in more than two years